Application of salvianolic acid C in preparation of medicine for treating doxorubicin cardiotoxicity
Activation of the AKT/JNK/Nrf2 pathway through sanphenolic acid C, combined with doxorubicin, solved the cardiotoxicity problem caused by doxorubicin, significantly improved cardiomyocyte viability, reduced heart damage, and expanded doxorubicin Clinical application of star.
Patent Information
- Application Number
- CN202411390271.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-30
- Publication Date
- 2024-11-15
AI Technical Summary
Doxorubicin has serious cardiotoxic side effects in clinical applications, and the existing treatment methods are limited and inaccurate, which affects its anti-tumor effect and aggravate myelosuppression caused by chemotherapy.
The combination of sanphenolic acid C and doxorubicin was used to activate the AKT/JNK/Nrf2 pathway, and oxidative stress and apoptosis induced by doxorubicin were inhibited, thereby reducing cardiotoxic side effects.
It significantly improves cardiomyocyte viability, reduces cardiac damage caused by doxorubicin, expands the clinical use range of doxorubicin, and has high safety and non-toxicity.
Smart Images

Figure CN118948829A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and specifically relates to a new use of salvianolic acid C, namely, the use of salvianolic acid C in counteracting the cardiotoxicity of doxorubicin, which can reduce the cardiotoxic side effects caused by doxorubicin.
[0002] Doxorubicin is an anthracycline antitumor antibiotic widely used in clinical practice. It can directly interfere with the structure and function of DNA and thus inhibit the proliferation of tumor cells. Currently, doxorubicin is suitable for the treatment of various tumors such as breast cancer, ovarian cancer, malignant lymphoma, acute leukemia, etc. However, it may have significant adverse effects on normal tissues, especially cardiac toxicity. Clinical studies have shown that when the cumulative dose of doxorubicin exceeds 600 mg / m 2 When the drug is used for treatment of leukemia, the incidence of adverse cardiac reactions in patients is as high as 36%, and it may even lead to congestive heart failure. Therefore, the cardiotoxicity of doxorubicin has largely limited the clinical application of doxorubicin.
[0003] Currently, there are limited effective means to treat doxorubicin cardiotoxicity. Dexrazoxane is the only adjuvant drug approved by the FDA to reduce anthracycline-induced cardiotoxicity, but its efficacy is uncertain and will affect the anti-tumor effect of doxorubicin and aggravate chemotherapy-induced bone marrow suppression. Given that doxorubicin is of great and irreplaceable significance for cancer patients in clinical treatment, the development of cardioprotective agents is of great practical significance for the safe clinical application of doxorubicin.
[0004] Danshen is the dried root and rhizome of the Lamiaceae plant Salvia miltiorrhiza. Modern pharmacological studies have shown that Danshen has a good cardiovascular and cerebrovascular protective effect, and its main active ingredients are water-soluble phenolic acid compounds (such as danshensu, etc.) and fat-soluble tanshinone compounds (such as tanshinone IIA, etc.).
[0005] In previous studies, the research team found that in the doxorubicin-induced cardiomyocyte injury model, salvianolic acid C can significantly improve cell viability and reduce the toxic effects of doxorubicin. Its activity is superior to that of the common main components of Danshen, such as tanshinone, salvianolic acid B, tanshinone IIA, and cryptotanshinone. At the same time, salvianolic acid C alone is non-toxic to cardiomyocytes and has high safety. Therefore, the combination of salvianolic acid C and doxorubicin is expected to reduce the cardiac toxicity caused by doxorubicin alone. However, there is no report on salvianolic acid C reducing the cardiac toxicity caused by doxorubicin. Summary of the invention
[0006] The purpose of the present invention is to provide a drug that can effectively improve doxorubicin-induced cardiotoxicity, and reduce the cardiotoxic side effects caused by doxorubicin alone through combined use.
[0007] To achieve the above object, the present invention adopts the following technical solution:
[0008] The present invention provides the use of salvianolic acid C in the preparation of a drug for treating cardiac damage caused by inhibition of the AKT / JNK / Nrf2 pathway. The CAS number of the salvianolic acid C is 115841-09-3, and the molecular formula is C 26 H 20 O 10 , molecular weight is 492.46.
[0009] The present invention shows that doxorubicin administration leads to inhibition of the AKT / JNK / Nrf2 pathway in cardiomyocytes, which in turn causes oxidative stress and apoptosis of cardiomyocytes, inducing cardiotoxicity. Salvianolic acid C can activate the AKT / JNK / Nrf2 pathway to improve doxorubicin-induced cardiac damage. Therefore, the use of salvianolic acid C can reverse the cardiotoxicity caused by inhibition of the AKT / JNK / Nrf2 pathway.
[0010] Furthermore, the drug is a drug for treating doxorubicin-induced cardiotoxic side effects. The present invention studies the mechanism of doxorubicin cardiotoxic side effects and finds that doxorubicin induces cardiotoxicity by inhibiting the AKT / JNK / Nrf2 pathway to cause oxidative stress and apoptosis of myocardial cells.
[0011] Furthermore, salvianolic acid C can improve doxorubicin-induced cardiac injury by activating the AKT / JNK / Nrf2 pathway.
[0012] Therefore, the combined use of salvianolic acid C and doxorubicin can inhibit doxorubicin-induced oxidative stress and apoptosis, thereby reducing the cardiac toxicity caused by doxorubicin alone.
[0013] Preferably, the effective dosage of salvianolic acid C in the drug is 5 to 20 mg / kg. This dosage is a safe and effective dosage.
[0014] Preferably, the drug further comprises a pharmaceutically acceptable carrier.
[0015] Another object of the present invention is to provide an anti-tumor combined drug, comprising a first preparation formed by salvianolic acid C and a pharmaceutically acceptable carrier, and a second preparation formed by doxorubicin and a pharmaceutically acceptable carrier.
[0016] The present invention provides an effective therapeutic drug for doxorubicin-induced cardiotoxicity. Studies have shown that compared with the doxorubicin monotherapy group, the combined use of salvianolic acid C can significantly improve myocardial cell viability and reduce cardiac damage in rats. In addition, the dosage of salvianolic acid C is low, and the monotherapy has no effect on animal survival, cardiac function, etc., indicating that salvianolic acid C is reasonable and safe as a protective agent.
[0017] Preferably, the mass ratio of salvianolic acid C to doxorubicin in the drug is 5 to 20:1, more preferably 20:1.
[0018] Preferably, the drug is administered in combination at a dosage of 15 mg / kg doxorubicin and 300 mg / kg salvianolic acid C.
[0019] The pharmaceutically acceptable carrier is a filler, a wetting agent, a binder, a disintegrant or a lubricant.
[0020] The dosage form of the drug is a liquid preparation or a solid preparation, including an oral solid preparation, an oral liquid preparation, an injection, a lyophilized powder injection, a large infusion dosage form, a patch, an ointment, a gel, a soft capsule or a suppository.
[0021] The present invention also provides the use of the anti-tumor combined drug in the preparation of drugs for treating breast cancer, lymphoma, osteosarcoma and leukemia.
[0022] The present invention has the following beneficial effects:
[0023] (1) The present invention provides a drug that can effectively improve doxorubicin-induced cardiotoxicity. Salvianolic acid C can protect the heart damage caused by doxorubicin by activating the myocardial AKT / JNK / Nrf2 pathway. The combined use of salvianolic acid C can reduce the severe heart damage caused by doxorubicin in tumor patients, thereby greatly expanding the clinical use of doxorubicin.
[0024] (2) Salvianolic acid C is a natural product derived from the traditional Chinese medicine Salvia miltiorrhiza. It has high safety and strong clinical feasibility. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 This is a comparison of the effects of salvianolic acid C, danshensu, salvianolic acid B, tanshinone IIA, and cryptotanshinone in reversing the cardiomyocyte survival rate reduced by doxorubicin.
[0026] Figure 2 Salvianolic acid C inhibits doxorubicin-induced oxidative stress in cardiomyocytes.
[0027] Figure 3 The figure shows that salvianolic acid C inhibits doxorubicin-induced cardiomyocyte apoptosis, where (A) is a representative figure of cell apoptosis detected by flow cytometry, and (B) is a statistical figure of cell apoptosis rate.
[0028] Figure 4 Salvianolic acid C improves doxorubicin-induced cardiac injury in rats, where (A) is the body weight gain value and (B) is the level of B-type natriuretic peptide (BNP).
[0029] Figure 5 The study showed that salvianolic acid C improves the pathological structural changes in rat heart tissue induced by doxorubicin.
[0030] Figure 6 Salvianolic acid C activates the expression of proteins related to the AKT / JNK / Nrf2 pathway which is inhibited by doxorubicin.
[0031] Figure 7 : Content (%) of Examples 1-4 and Comparative Examples 1-4 at 0, 1, 2, 3, and 6 months after accelerated testing.
[0032] Figure 8 : The contents of related impurities (%) in Examples 1-4 and Comparative Examples 1-4 at 0, 1, 2, 3 and 6 months after the accelerated test.
[0033] Fig. 9 : Total miscellaneous related substance contents (%) of Examples 1-4 and Comparative Examples 1-4 at 0, 1, 2, 3, and 6 months after the accelerated test.
[0034] Fig.10 : The re-dissolution time (s) of Examples 1-4 and Comparative Examples 1-4 at 0, 1, 2, 3, and 6 months after the accelerated test. DETAILED DESCRIPTION
[0035] The present invention will be further described below in conjunction with specific embodiments. The following embodiments are only used to illustrate the present invention and are not intended to limit the scope of application of the present invention. Without departing from the spirit and essence of the present invention, modifications or replacements made to the inventive method, steps or conditions all belong to the scope of the present invention.
[0036] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods; the materials and reagents used are reagents and materials that can be obtained from commercial channels unless otherwise specified.
[0037] Male Sprague–Dawley rats were purchased from the Experimental Animal Center of Zhejiang Academy of Medical Sciences; the brain natriuretic peptide kit was purchased from Shanghai Shenggong Bioengineering Co., Ltd.; rat H9c2 cardiomyocytes were purchased from Procell Biotechnology Co., Ltd.; AKT and p-AKT antibodies were purchased from Cell Signaling Technology; JNK and p-JNK antibodies were purchased from Abcam; Nrf2 antibody was purchased from Proteintech; GAPDH antibody was purchased from Hangzhou Daige Biotechnology Co., Ltd.; reactive oxygen species detection kit was purchased from Shanghai Biyuntian Biotechnology Co., Ltd.; and apoptosis detection kit was purchased from Hangzhou Lianke Biotechnology Co., Ltd.
[0038] Doxorubicin, CAS number is 23214-92-8, molecular formula is C 27 H 29 NO 11 , molecular weight 543.527, purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. The structural formula is as follows:
[0039]
[0040] Salvianolic acid C, CAS number is 115841-09-3, molecular formula is C 26 H 20 O 10 , molecular weight 492.439, purchased from Chengdu Munster Co., Ltd. The structural formula is as follows:
[0041]
[0042] Example 1
[0043] 1. Rat H9c2 cardiomyocytes were used as the research objects, and 8 groups were set up, namely blank control group (CON), doxorubicin group (DOX), salvianolic acid C group (SAC), salvianolic acid C combined group (DOX-SAC), tanshinone combined group (DOX-DSS), salvianolic acid B combined group (DOX-SAB), tanshinone IIA combined group (DOX-TSA) and cryptotanshinone combined group (DOX-CTS). The dose of doxorubicin was 0.5μM, the dose of salvianolic acid C, tanshinone, salvianolic acid B, tanshinone IIA and cryptotanshinone was 45μM, and the control group was solvent dimethyl sulfoxide (DMSO). After 48h of co-administration, the survival rate of cardiomyocytes was detected by CCK-8 method. The calculation formula is: cell survival rate of drug administration group = (absorbance value of drug administration group - absorbance value of blank group) / (absorbance value of control group - absorbance value of blank group) × 100%.
[0044] The experimental results are described in detail as follows: Figure 1As shown, the survival rates of H9c2 cardiomyocytes in the control group, doxorubicin group, salvianolic acid C group, salvianolic acid C combined group, danshensu combined group, salvianolic acid B combined group, tanshinone IIA combined group and cryptotanshinone combined group were 100.0±0.00%, 23.95±4.13%, 102.26±1.48%, 51.97±5.77%, 20.95±0.52%, 30.13±0.55%, 20.21±2.72% and 14.79±1.05%, respectively. Compared with the doxorubicin alone group, the cell survival rate of the salvianolic acid C combined group was significantly increased (P<0.05), indicating that the combined use of salvianolic acid C can significantly improve the survival rate of cardiomyocytes under the action of doxorubicin. In addition, compared with tanshinone, salvianolic acid B, tanshinone IIA, and cryptotanshinone, the cell survival rate of the group taking salvianolic acid C was higher (all P less than 0.05), indicating that salvianolic acid C exhibits superior activity in reversing doxorubicin cardiotoxicity than the aforementioned compounds.
[0045] 2. Rat H9c2 cardiomyocytes were used as the research objects, and four groups were set up, namely control group, doxorubicin group, salvianolic acid C group and combined group. The dose of doxorubicin was 0.5μM, the dose of salvianolic acid C was 100μM, and the control group was solvent dimethyl sulfoxide (DMSO). After 24 hours of co-administration, the level of reactive oxygen species (ROS) in the cells was detected using a reactive oxygen species detection kit.
[0046] The experimental results are described in detail as follows: Figure 2 As shown in the figure, compared with the control group and the group using salvianolic acid C alone, the green fluorescence intensity of the doxorubicin group was significantly enhanced, indicating that doxorubicin can increase the level of ROS in cardiomyocytes and cause oxidative stress damage. After the combination with salvianolic acid C, the green fluorescence was significantly weakened, indicating that salvianolic acid C can reduce the accumulation of ROS in cardiomyocytes caused by doxorubicin.
[0047] 3. Rat H9c2 cardiomyocytes were used as the research object, and four groups were set up, namely the control group, doxorubicin group, salvianolic acid C group and combined group. The dose of doxorubicin was 0.5μM, the dose of salvianolic acid C was 100μM, and the control group was solvent dimethyl sulfoxide (DMSO). After 24 hours of co-administration, the apoptosis rate of cardiomyocytes was detected by flow cytometry combined with AnnexinV-FITC / PI staining.
[0048] The experimental results are described in detail as follows: Figure 3As shown in the figure, the apoptosis rates of H9c2 cardiomyocytes in the control group, doxorubicin group, salvianolic acid C group and combined group were 2.80±1.46%, 40.20±0.68%, 4.41±1.66% and 17.78±0.96%, respectively. Compared with the doxorubicin group, the apoptosis rate of the combined group was significantly reduced (P<0.05), indicating that the combined use of salvianolic acid C can significantly reverse the doxorubicin-induced cardiomyocyte apoptosis.
[0049] Example 2
[0050] 1. Twenty male SD rats were randomly divided into 4 groups, namely control group, doxorubicin group, salvianolic acid C group, and doxorubicin + salvianolic acid C combined group, with 5 rats in each group, and the drugs were administered by intraperitoneal injection. The dose of doxorubicin was 2.5 mg / kg / day, once every two days, for a total of 6 times, with a cumulative dose of 15 mg / kg; the dose of salvianolic acid C was 20 mg / kg / day; the control group was replaced with 0.9% normal saline. After 15 consecutive days of administration, the rats were weighed and the body weight gain was calculated. The calculation formula was: body weight gain = (final body weight - initial body weight) / initial body weight × 100. Blood samples were collected by abdominal aorta blood sampling to detect the level of B-type brain natriuretic peptide (BNP), an indicator of cardiac injury in serum. The rats were then killed, the hearts were dissected, and the heart tissues were embedded, sliced, and HE stained.
[0051] The results of rat body weight gain are as follows Figure 4 As shown in A, the body weight gain values of the control group, doxorubicin group, salvianolic acid C group and combination group were 62.90±7.32%, 34.82±2.24%, 62.67±4.42% and 58.86±5.56% respectively. Compared with the doxorubicin group alone, the body weight gain value of the combination group was significantly increased (P<0.05).
[0052] BNP test results Figure 4 As shown in B, the levels of cardiac function index BNP in the control group, doxorubicin group, salvianolic acid C group and combined group were 43.50±1.39, 85.30±2.33, 45.60±2.70 and 65.96±3.78 pg / mL, respectively. The BNP level in the combined group was significantly lower than that in the doxorubicin group (P<0.05).
[0053] The above data indicate that doxorubicin can cause cardiac function damage in rats, and the cardiac function damage induced by doxorubicin in rats was significantly reversed after the combined use of salvianolic acid C.
[0054] HE staining was performed on the heart tissue sections. Figure 5 The disordered arrangement of myocardial cells, cytoplasmic vacuolization and myofiber degeneration caused by doxorubicin alone were significantly improved after combined use of salvianolic acid C.
[0055] 2. Western blot was used to detect the expression levels of AKT, p-AKT, JNK, p-JNK and Nrf2 proteins in the myocardium after administration. Figure 6 As shown in the figure, compared with the control group, doxorubicin significantly regulated the phosphorylation of AKT and JNK and reduced the level of Nrf2. However, this phenomenon was significantly reversed after the combination of salvianolic acid C.
[0056] Example 3: Preparation of a pharmaceutical preparation of salvianolic acid C and doxorubicin
[0057] Example 1: An injection containing salvianolic acid C and doxorubicin
[0058] Prescription for 1000
[0059] Element g Doxorubicin 15 Salvianolic acid C 300 Mannitol 55 n-Butanol 11 servings Citric acid Moderate Water for injection Moderate
[0060] The preparation process is as follows:
[0061] (1) Add appropriate amount of injection water to weigh mannitol and stir to dissolve, add n-butanol and stir to dissolve, then add doxorubicin and stir to dissolve completely;
[0062] (2) Add activated carbon and filter, decarbonize for 10-15 minutes;
[0063] (3) Add water for injection to the full volume and adjust the pH to 5.0-6.0 with citric acid;
[0064] (4) Fill the drug solution into a vial and freeze-dry.
[0065] Freeze-drying curve: cool to -35±5℃ for pre-freezing, keep for 2 hours; heat to -15±5℃, keep warm for 1.5 hours, cool to -35±5℃, keep warm for 2 hours; open the cold trap, open the vacuum; heat the partition to -10℃, and keep warm for 12 hours; heat the partition to 0℃, and keep warm for 4 hours; heat the partition to 33℃, and keep warm for 4 hours; remove from the pot after freeze-drying. Example 2: An injection containing salvianolic acid C and doxorubicin
[0066] Prescription for 1000
[0067] Element g Doxorubicin 5 Salvianolic acid C 100 Mannitol 10 n-Butanol 5 Citric acid Moderate Water for injection Moderate
[0068] The preparation process is the same as Example 1.
[0069] Example 3: A prescription for 1,000 injections containing salvianolic acid C and doxorubicin
[0070] Element g Doxorubicin 20 Salvianolic acid C 200 Mannitol 100 n-Butanol 17 Citric acid Moderate Water for injection Moderate
[0071] The preparation process is the same as Example 1.
[0072] Example 4: A prescription for 1,000 injections containing salvianolic acid C and doxorubicin
[0073] Element g Doxorubicin 10 Salvianolic acid C 200 Mannitol 300 n-Butanol 30 Citric acid Moderate Water for injection Moderate
[0074] Preparation process:
[0075] Add the prescribed amount of mannitol to water for injection, stir to dissolve, add 0.1% activated carbon for injection, stir for 10 minutes, filter to remove carbon; add doxorubicin and salvianolic acid C to the filtrate, stir to completely dissolve; add water for injection to the full amount, circulate and filter to mix evenly, and adjust the pH of the drug solution to 5.0-6.0; fill in an ampoule bottle, fill the ampoule with nitrogen before filling, seal it with a sealant, check for leaks, and sterilize to obtain the product.
[0076] Example 5: A capsule containing salvianolic acid C and doxorubicin
[0077] Prescription for 1000
[0078] Element g Doxorubicin 10 Salvianolic acid C 200 Mannitol 300 n-Butanol 30 Citric acid Moderate Water for injection Moderate
[0079] The preparation process is as follows:
[0080] 1) weighing 90% by weight of microcrystalline cellulose, 90% by weight of low-substituted hydroxypropyl cellulose, 90% by weight of colloidal silicon dioxide and salvianolic acid C, adding them to a dry granulator and mixing them to obtain granulation I;
[0081] 2) weighing 10% by weight of microcrystalline cellulose, 10% by weight of low-substituted hydroxypropyl cellulose, 10% by weight of colloidal silicon dioxide and doxorubicin, adding them to a dry granulator and mixing them to obtain granulation II;
[0082] 3) Add granulation I and granulation II to magnesium stearate and mix at a speed of 10 rp / min for 8 minutes, and then fill into capsules.
[0083] Comparative Example 1: An injection containing salvianolic acid C and doxorubicin
[0084] Prescription for 1000
[0085] Element g Doxorubicin 10 Salvianolic acid C 200 Mannitol 300 Tert-Butanol 30 Citric acid Moderate Water for injection Moderate
[0086] The preparation process is the same as in Example 1:
[0087] Comparative Example 2: An injection containing salvianolic acid C and doxorubicin
[0088] Prescription for 1000
[0089] Element g Doxorubicin 10 Salvianolic acid C 40 Mannitol 100 n-Butanol 20 Citric acid Moderate Water for injection Moderate
[0090] The preparation process is the same as in Example 1:
[0091] Comparative Example 3: An injection containing salvianolic acid C and doxorubicin
[0092] Prescription for 1000
[0093] Element g Doxorubicin 10 Salvianolic acid C 200 Sorbitol 300 Maltitol 30 Citric acid Moderate Water for injection Moderate
[0094] The preparation process is the same as in Example 1:
[0095] Comparative Example 4: An injection containing salvianolic acid C and doxorubicin
[0096] Prescription for 1000
[0097] Element g Doxorubicin 10 Salvianolic acid B 200 Mannitol 300 n-Butanol 30 Citric acid Moderate Water for injection Moderate
[0098] The preparation process is the same as in Example 1:
[0099] Verification Example: Test according to the 2020 edition of the Chinese Pharmacopoeia Part II Stability Test Guidelines for APIs and Pharmaceutical Preparations.
[0100] [Content determination] Determine according to high performance liquid chromatography (General Rule 0512).
[0101] Chromatographic conditions and system suitability test: Octadecylsilane bonded silica gel was used as filler; sodium dodecyl sulfate solution (1.44 g of sodium dodecyl sulfate and 0.68 ml of phosphoric acid were taken, and 500 ml of water was added to dissolve)-acetonitrile-methanol (500:500:60) was used as mobile phase; the detection wavelength was 254 nm; appropriate amounts of doxorubicin hydrochloride reference substance and epirubicin hydrochloride reference substance were taken, dissolved in the mobile phase and diluted to make a mixed solution containing 50 μg of each in each ml, 10 μl was taken and injected into the liquid chromatograph, and the chromatogram was recorded. The separation degree between the doxorubicin peak and the epirubicin peak should be greater than 2.0.
[0102] Specifically in the present invention: 10 bottles of Examples 1-4 and Comparative Examples 1-4 were taken, and the mobile phase was added according to the labeled amount to dissolve and quantitatively diluted to prepare a solution containing about 0.1 mg per 1 ml, which was used as the test solution, and the doxorubicin hydrochloride was measured according to the method, and the average content of the 10 bottles was calculated.
[0103] [Related substances] Take appropriate amounts of Examples 1-4 and Comparative Examples 1-4, dissolve and dilute with mobile phase to prepare a solution containing 1.0 mg of doxorubicin hydrochloride per 1 ml, as the test solution, and determine according to the method under doxorubicin hydrochloride. The peak area of doxorubicin ketone (take about 10 mg of doxorubicin hydrochloride reference substance, add 5 ml of water and 5 ml of phosphoric acid, shake well, let stand for 30 minutes, adjust the pH value to 2.6 with 2 mol / L sodium hydroxide solution, add 15 ml of acetonitrile and 10 ml of methanol, mix well, and obtain doxorubicin ketone reference solution) shall not be greater than the main peak area of the reference solution (1.0%); the peak area of other individual impurities shall not be greater than 0.5 times the main peak area of the reference solution (0.5%), and the sum of the peak areas of each impurity shall not be greater than 3 times the main peak area of the reference solution (3.0%).
[0104] Reconstitution time of lyophilized powder: Add 0.9% saline to the lyophilized powder and start timing immediately. During the dissolution process, pay attention to the dissolution of the lyophilized powder and avoid violent shaking so as not to affect the results. When the lyophilized powder is completely dissolved and the solution is uniform and free of particles, stop timing and record the required time.
[0105] Results
[0106] Figure 7 : Content (%) of Examples 1-4 and Comparative Examples 1-4 at 0, 1, 2, 3, and 6 months after accelerated testing.
[0107] Figure 8 : The contents of related impurities (%) in Examples 1-4 and Comparative Examples 1-4 at 0, 1, 2, 3 and 6 months after the accelerated test.
[0108] Fig. 9 : Total miscellaneous related substance contents (%) of Examples 1-4 and Comparative Examples 1-4 at 0, 1, 2, 3, and 6 months after the accelerated test.
[0109] Fig.10 : The re-dissolution time (s) of Examples 1-4 and Comparative Examples 1-4 at 0, 1, 2, 3, and 6 months after the accelerated test.
Claims
1. Use of salvianolic acid C in the preparation of a drug for preventing or treating cardiac toxic side effects induced by doxorubicin, characterized in that: The structural formula of the salvianolic acid C is shown in formula (I), 2. The use according to claim 1, characterized in that The doxorubicin induces cardiac toxicity by inhibiting the AKT / JNK / Nrf2 pathway; the cardiac toxicity includes disordered arrangement of myocardial cells, cytoplasmic vacuolization and myofiber degeneration.
3. The use according to claim 1, characterized in that The salvianolic acid C improves doxorubicin-induced cardiac injury by activating the AKT / JNK / Nrf2 pathway.
4. The use according to claim 1, characterized in that: The effective dosage of salvianolic acid C in the medicine is 5-20 mg / kg.
5. An anti-tumor combined drug, characterized in that: The invention comprises a first preparation formed by salvianolic acid C and a pharmaceutically acceptable carrier, and a second preparation formed by doxorubicin and a pharmaceutically acceptable carrier; salvianolic acid C improves doxorubicin-induced cardiac damage by activating the AKT / JNK / Nrf2 pathway; the cardiac damage induced by doxorubicin is manifested as disordered arrangement of cardiomyocytes, cytoplasmic vacuolation and myofiber degeneration; doxorubicin inhibits the AKT / JNK / Nrf2 pathway, causing oxidative stress and apoptosis of cardiomyocytes, thereby inducing cardiac toxicity.
6. The anti-tumor combination drug according to claim 3, characterized in that: The mass ratio of salvianolic acid C to doxorubicin in the drug is 5 to 20:1, and more preferably 20:
1.
7. The anti-tumor combination drug according to claim 3, characterized in that: The pharmaceutically acceptable carrier is one or more of a filler, a wetting agent, a binder, a disintegrant, a lubricant, a solvent, citric acid, an antioxidant, a complexing agent, an isotonicity regulator, a solubilizer, an antibacterial agent, a suspending agent, and an emulsifier.
8. The anti-tumor combination drug according to claim 3, characterized in that: The preparations are tablets, granules, capsules, oral liquids and injections.
9. The anti-tumor combination drug according to claim 3, characterized in that: The prescription of the tablet is: The preparation process is as follows: 1) weighing 90% by weight of microcrystalline cellulose, 90% by weight of low-substituted hydroxypropyl cellulose, 90% by weight of colloidal silicon dioxide and salvianolic acid C, adding them to a dry granulator and mixing them to obtain granulation I; 2) weighing 10% by weight of microcrystalline cellulose, 10% by weight of low-substituted hydroxypropyl cellulose, 10% by weight of colloidal silicon dioxide and doxorubicin, adding them to a dry granulator and mixing them to obtain granulation II; 3) Granulation I and granulation II were added with magnesium stearate and mixed at a speed of 10 rp / min for 8 minutes, and tablets were obtained.
10. Use of the anti-tumor combination drug according to any one of claims 3 to 7 in the preparation of drugs for treating breast cancer, lymphoma, osteosarcoma and leukemia.
Citation Information
Cited By
Application of przewatanshinone A in preparation of medicine for treating anti-tumor medicine cardiotoxicity
CN121287722A
